KET is the prototypical non-competitive antagonist at N -methyl-D-aspartate glutamate receptors and a clinically approved anesthetic
Back Deacon, DF, Johnsen, AH, Holst, JJ (March 1995) 'Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo', Journal Clinical Endocrinology Metabolism , 80/3, 952-7
Combining them should only be done under medical guidance so dosing, timing, and your response can be monitored carefully and adjusted as needed
Yet week after week, the scale barely budged
Does Ipamorelin improve Retatrutide weight loss
chinensis by mediating Pb accumulation and transport (Yuan et al., 2015)